Compositions for topical treatment to reduce the appearance of the hyperpigmented lesions of melasma are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied gel, lotion, wash, shampoo, cream, or mask. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided.

Compositions for topical treatment to reduce the appearance of the hyperpigmented lesions of melasma are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied gel, lotion, wash, shampoo, cream, or mask. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided.

Cationic pillar[n]arenes, e.g., positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillar[5-6]arene derivatives are capable of inhibiting or preventing biofilm formation, and facilitating existing biofilm decomposition. A composition for inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm, can include a pharmaceutically acceptable carrier, and a cationic pillar[n]ene.

Cationic pillar[n]arenes, e.g., positively charged poly-ammonium, poly-phosphonium and poly-imidazolium pillar[5-6]arene derivatives are capable of inhibiting or preventing biofilm formation, and facilitating existing biofilm decomposition. A composition for inhibiting or disrupting biofilm, e.g., bacterial or fungal biofilm, formation, or reducing biofilm, can include a pharmaceutically acceptable carrier, and a cationic pillar[n]ene.

This invention relates to a series of binuclear palladacycle compounds, and methods for the production of these compounds, that are suitable for use in the treatment of cancer. In particular embodiments, R.sup.1 is phenyl substituted with two occurrences of isopropyl, R.sup.2 is Cl, and R.sup.3 is independently one or more substituents selected from —O(CH.sub.2).sub.2O(CH.sub.2).sub.2OH, —O(CH.sub.2).sub.2O(CH.sub.2).sub.2O(CH.sub.2).sub.2OH, —O(CH.sub.2).sub.2OH, and —O(CH.sub.2).sub.2O(CH.sub.2).sub.2OCH.sub.3.

This invention relates to a series of binuclear palladacycle compounds, and methods for the production of these compounds, that are suitable for use in the treatment of cancer. In particular embodiments, R.sup.1 is phenyl substituted with two occurrences of isopropyl, R.sup.2 is Cl, and R.sup.3 is independently one or more substituents selected from —O(CH.sub.2).sub.2O(CH.sub.2).sub.2OH, —O(CH.sub.2).sub.2O(CH.sub.2).sub.2O(CH.sub.2).sub.2OH, —O(CH.sub.2).sub.2OH, and —O(CH.sub.2).sub.2O(CH.sub.2).sub.2OCH.sub.3.

The present invention relates to a process for preparing antibody-drug conjugates wherein therapeutic moieties are conjugated to one or more engineered cysteines as well as to one or more reduced interchain cysteines via a cleavable or non-cleavable linker.

The present invention relates to a process for preparing antibody-drug conjugates wherein therapeutic moieties are conjugated to one or more engineered cysteines as well as to one or more reduced interchain cysteines via a cleavable or non-cleavable linker.

The present invention features methods and composition directed to treating neuronal injury, CNS lesion, and/or promoting axon regeneration using a phosphine sulfide-stabilized phosphine.

The present invention features methods and composition directed to treating neuronal injury, CNS lesion, and/or promoting axon regeneration using a phosphine sulfide-stabilized phosphine.